Skip to main content
SpringerLink
Log in

Conclusions and Take Home Message

  • Chapter
Combination Therapy In Dyslipidemia

  • 687 Accesses

Abstract

Based on the data included in the chapters the following conclusions and take-home messages might be presented:

Declaration of Interest 

MB has given lectures, received honoraria or research support, and participated in conferences, advisory boards and clinical trials sponsored by Abbott, Abbott Vascular, Amgen, Daiichi-Sankyo, MSD, and Sanofi-Regeneron.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Toth PP, Nikolic D, Rizzo M, Rysz J, Banach M. Use of combination statin and bile acid sequestrant therapy to treat dyslipidemia. In: Banach M, editor. Combination therapy in dyslipidaemia. 1st ed. Springer; 2015. pp. 1–10.

    Google Scholar 

  2. Chruściel P, Mikhailidis DP, Toth PP, Rysz J, Banach M. Statins and fibrates – should it be recommended? In: Banach M, editor. Combination therapy in dyslipidaemia. 1st ed. Springer; 2015. pp. 11–24.

    Google Scholar 

  3. Nikolic D, Katsiki N, Toth PP, Banach M, Al-Waili K, Al-Rasadi K, Rizzo M, Mikhailidis DP. Drug Evaluation. The Combination of fenofibrate and simvastatin for the treatment of dyslipidemia: when and for whom? In: Banach M, editor. Combination therapy in dyslipidaemia. 1st ed. Springer; 2015. pp. 179–90.

    Google Scholar 

  4. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015 Jun 3. [Epub ahead of print]; doi:10.1056/NEJMoa1410489.

  5. Laufs U. Statins and ezetimibe – doubts or bright future? In: Banach M, editor. Combination therapy in dyslipidaemia. 1st ed. Springer; 2015. pp. 25–36.

    Google Scholar 

  6. HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, Wallendszus K, Craig M, Jiang L, Collins R, Armitage J. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203–12.

    Article  Google Scholar 

  7. Agouridis AP, Mikhailidis DP. Statins and niacin – the end of residual risk therapy? In: Banach M, editor. Combination therapy in dyslipidaemia. 1st ed. Springer; 2015. pp. 37–44.

    Google Scholar 

  8. Brandt EJ, Davidson MH. The role of omega-3 fatty acids in dyslipidemias. In: Banach M, editor. Combination therapy in dyslipidaemia. 1st ed. Springer; 2015. pp. 45–64.

    Google Scholar 

  9. Nicholls SJ. Statins and CETP inhibitors – anacetrapib and evacetrapib – the last hope? In: Banach M, editor. Combination therapy in dyslipidaemia. 1st ed. Springer; 2015. pp. 65–72.

    Google Scholar 

  10. Pang J, Chan DC, Watts GF. Statins and mipomersen – mechanisms of action and patient tolerability. In: Banach M, editor. Combination therapy in dyslipidaemia. 1st ed. Springer; 2015. pp. 73–86.

    Google Scholar 

  11. Pirillo A, Catapano AL. Statins and lomitapide – a suitable response for homozygous familial hypercholesterolemia? In: Banach M, editor. Combination therapy in dyslipidaemia. 1st ed. Springer; 2015. pp. 87–98.

    Google Scholar 

  12. Dragan S, Serban MC, Banach M. Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy? J Cardiovasc Pharmacol Ther. 2015;20(2):157–68.

    Article  CAS  PubMed  Google Scholar 

  13. Banach M, Rizzo M, Toth PP, et al. Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci. 2015;11(1):1–23.

    Article  PubMed Central  PubMed  Google Scholar 

  14. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA, Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1500–9.

    Article  CAS  PubMed  Google Scholar 

  15. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ, ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489–99.

    Article  CAS  PubMed  Google Scholar 

  16. Farnier M. Statins and PCSK9 inhibitors: defining the correct patients. In: Banach M, editor. Combination therapy in dyslipidaemia. 1st ed. Springer; 2015. pp. 99–118.

    Google Scholar 

  17. Kostner K. Other possible drug combinations for dyslipidaemia. In: Banach M, editor. Combination therapy in dyslipidaemia. 1st ed. Springer; 2015. pp. 119–26.

    Google Scholar 

  18. Zhao Y, Wong ND. Combination of lipid lowering agents with antihypertensive drugs – a joint fight against the two most important risk factors? In: M Banach, editor. Combination therapy in dyslipidaemia. 1st ed. Springer; 2015. pp. 153–64.

    Google Scholar 

  19. Gozdzikiewicz-Lapinska J, Malyszko J. Drug evaluation: olmesartan medoxomil + rosuvastatin for the treatment of dyslipidemia and concomitant risk factors: a chance for better compliance? In: Banach M, editor. Combination therapy in dyslipidaemia. 1st ed. Springer; 2015. pp. 191–200.

    Google Scholar 

  20. Lafeber M. The cardiovascular polypill in the prevention of cardiovascular disease. In: Banach M, editor. Combination therapy in dyslipidaemia. 1st ed. Springer; 2015. pp. 165–78.

    Google Scholar 

  21. Cicero AFG, Colletti A. Statins and nutraceuticals/functional food – could be they combined? In: Banach M, editor. Combination therapy in dyslipidaemia. 1st ed. Springer; 2015. pp. 127–42.

    Google Scholar 

  22. Serban C, Sahebkar A, Ursoniu S, Andrica F, Banach M. Effect of sour tea (Hibiscus sabdariffa L.) on arterial hypertension: a systematic review and meta-analysis of randomized controlled trials. J Hypertens. 2015;33(6):1119–27.

    Article  CAS  PubMed  Google Scholar 

  23. Sahebkar A, Serban MC, Ursoniu S, Banach M. Effect of curcuminoids on oxidative stress: a systematic review and meta-analysis of randomized controlled trials. J Funct Food. 2015. doi:10.1016/j.jff.2015.01.005.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hypertension, WAM University Hospital in Lodz, Medical University of Lodz, Zeromskiego 113, Lodz, 90-549, Poland

    Maciej Banach MD, PhD, FNLA, FAHA, FESC, FASA

Authors
  1. Maciej Banach MD, PhD, FNLA, FAHA, FESC, FASA
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maciej Banach MD, PhD, FNLA, FAHA, FESC, FASA .

Editor information

Editors and Affiliations

  1. Department of Hypertension, WAM University Hospital in Lodz, Medical University of Lodz, Lodz, Poland

    Maciej Banach

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Banach, M. (2015). Conclusions and Take Home Message. In: Banach, M. (eds) Combination Therapy In Dyslipidemia. Adis, Cham. https://doi.org/10.1007/978-3-319-20433-8_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-20433-8_17

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-20432-1

  • Online ISBN: 978-3-319-20433-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation